Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pinpointing the potential hits for hindering interaction of SARS-CoV-2 S-protein with ACE2 from the pool of antiviral phytochemicals utilizing molecular docking and molecular dynamics (MD) simulations

Chirag N. Patel a,1, Dweipayan Goswami b,1, Dharmesh G. Jaiswal a, Robin M. Parmar c, Hitesh A. Solanki a, Himanshu A. Pandya a,∗

a Department of Botany, Bioinformatics, and Climate Change Impacts Management, School of Sciences, Gujarat University, Ahmedabad, 380009, India
b Department of Microbiology & Biotechnology, School of Sciences, Gujarat University, Ahmedabad, 380009, Gujarat, India
c Department of Zoology, School of Sciences, Gujarat University, Ahmedabad, 380009, India

Article info
Article history:
Received 9 December 2020
Received in revised form
25 January 2021
Accepted 10 February 2021
Available online 22 February 2021

Keywords:
SARS-CoV-2 novel coronavirus
S-Protein blocker
Antiviral phytochemicals
Molecular dynamics (MD) simulation

Abstract
SARS-CoV-2, the viral particle, is responsible for triggering the 2019 Coronavirus disease outbreak (COVID-19). To tackle this situation, a number of strategies are being devised to either create an antidote, a vaccine, or agents capable of preventing its infection. To enable research on these strategies, numerous target proteins are identified where Spike (S) protein is presumed to be of immense potential. S-protein interacts with human angiotensin-converting-enzyme-2 (ACE2) for cell entry. The key region of S-protein that interacts with ACE2 is a portion of it designated as a receptor-binding domain (RBD), following whereby the viral membrane fuses with the alveolar membrane to enter the human cell. The proposition is to recognize molecules from the bundle of phytochemicals of medicinal plants known to possess antiviral potentials as a lead that could interact and mask RBD, rendering them unavailable to form ACE2 interactions. Such a molecule is called the ‘S-protein blocker’. A total of 110 phytochemicals from Withania somnifera, Asparagus racemosus, Zinziber officinalis, Allium sativum, Curcuma longa and Adhatoda vasica were used in the study, of which Racemoside A, Ashwagandhanolide, Withanoside VI, Withanoside IV and Racemoside C were identified as top five hits using molecular docking. Further, essential Pharmacophore features and their ADMET profiles of these compounds were studied following to which the best three hits were analyzed for their interaction with RBD using Molecular Dynamics (MD) simulation. Binding free energy calculations were performed using MM/GBSA, proving these phytochemicals can serve as S-protein blocker.

© 2021 Elsevier Inc. All rights reserved.

1. Introduction

The reparations of novel Severe Acute Respiratory Syndrome Virus-Coronavirus-2 (SARS-CoV-2) is severe, and it is hard to come over with the situation of pandemic even after a year of its onset. There has been no focused drug to stop the spread and replication of this viral particle in human host [1,2]. Regardless of being flabbergasted from the circumstance of pandemic rose by SARS-CoV-2, people of scientific and clinical society are aggregately attempting to discover an immunization or to build up a technique to battle the mind-boggling virus, SARS-CoV-2 [3–5]. According to the details of the World health organization (WHO), worldwide ~25 million people have been affected by the infection of SARS-CoV-2 of which ~0.85 million passings have occurred (https://covid19.who.int/). According to the description of the International Committee on Taxonomy of Viruses (ICTV), this pandemic causing infection is hereditarily alike the SARS-CoV infection causing the flare-up of 2003; thus, the identified virus was assigned as SARS-CoV-2 on eleventh of February 2020 [6]. Albeit hereditarily related, the two infection strains are unique in their strength of causing disease, where the latest identified novel coronavirus is known to be quickly contracting and shows moderately lower mortality, notwithstanding, its high infectivity has made this viral infection spread all
around the world in an exceptionally brief timeframe. It fundamentally causes a respiratory or gastrointestinal disease with the effects like fever, pneumonia, windedness in certain populations [7]. It is unavoidable to recognize a vaccine or a helpful drug that can function as a counteractant or that can debilitating the virus causing a decrease in its spread.

Apart from discovering the vaccine, there exists two main strategies to control CoVs, for the researchers on working on the alternative strategy of developing the anti-viral drug, that is by identifying or developing inhibitors (i) to impede viral passage into the host cells, and (ii) to forestall viral replication [5]. For these reasons, an aggregate of twelve proteins distinguished as targets which are comprehensively delegated are (i) Structural Proteins and (ii) Non-structural protein. Structural proteins, namely Spike protein (S-protein), Envelop small membrane protein (E-protein), Membrane protein (M-protein), Nucleocapsid protein (N-protein), are significant for accomplishing the virulent viral physical conformation. Causing bending or misfolding of these proteins is focused on essentially lessening the harmfulness and infectivity of the virus. S-protein is considered to have more noteworthy structural-functional significance and it turns into a conspicuous decision to be a significant target protein. Non-structural proteins, namely Main protease (Mpro), Papain-like function, Non-structural protein (nsp)-10, nsp-11, nsp-13, nsp-14, nsp-15 and nsp-16 are needed for replication and bundling of the virus particle into the capsid protein coat [2,8] thus these proteins are being viewed as targets on the grounds that hindering any of these proteins can stop viral load increase in host cell [6,8,9].

Of the clear large number of structural proteins, S-protein is foreseen to be the main protein for being a potential target. This is on the grounds that S-protein is the principal protein to communicate with the human host by interacting with human angiotensin-converting enzyme 2 (ACE2) for entering the human cell. The receptor-binding domain (RBD), of S-protein, comprises of S1 and S2 subunits. S1 subunits use human ACE2 as the receptor to infect human cells and the S2 subunit intervenes the membrane fusion process, for example fusion of viral membrane with human cell membrane [10–13].

RBD serves as a potential target, if masked with a small molecule, its interaction with ACE2 can be halted. Interaction of RBD with ACE2 is a complex mechanism that occurs on the cell membrane of alveolar cells. The theory is to recognize molecules as a lead having capacity to explicitly interact and mask critical amino acids of RBD, making them inaccessible to interact with ACE2 at the alveolar membrane [14]. Small molecules or bioactive compounds that restrain or forbid the merging of viral membrane with the host's cell membrane by any mechanism can be designated as 'S-protein inhibitors'. Moreover, these small bioactive molecules are also to be accessed for their ADMET (Absorption–Distribution–Metabolism–Excretion–Toxicity) and pharmacophore properties to predict their availability on the alveolar membrane for S-protein to interact in priority to that of ACE2. One of the most well-perceived research in developing S-protein inhibitors was by developing a peptide known designated as 'pan-coronavirus fusion inhibitor targeting peptide EK1' works by disallowing the fusion of viral membrane with human cell's membrane [15]. Notwithstanding, EK1 being peptide can’t be consumed orally however was proposed to be managed by nasal course making it hard to utilize [15,16]. Moreover, EK1 was also prone to protease degradation by membrane proteases reducing its shelf life and therefore, molecules with a similar function possessing capacity administered orally is being searched for. In this context, recent research is performed and Glycyrrhiza glabra has shown properties of being a S-protein inhibitors predicted using Docking and Molecular Dynamics (MD) simulation [17]. Despite a modest bunch of endeavours been sought after, there exists huge degree for distinguishing more up to date S-protein inhibitors against SARS-CoV-2.

To deliver such lead compounds to hit the commercial market, it is essential for them to not show toxicity, and so selecting a library of compounds for such assessment becomes very important. One hundred ten phytochemicals were selected from various medicinal plants like Withania somnifera, Asparagus racemosus, Zinziber officinalis, Allium sativum, Curcuma longa and Adhatoda vasica based on their previous reports of showing antiviral activity against other viruses. Here we hypothesized to identify S-protein inhibitors from the library of antiviral phytochemicals that are already known for their beneficial implications on human health using Docking and Molecular Dynamics (MD) simulation.

2. Materials and methods

2.1. Spike protein assessment for identifying correct docking site

S-protein in general is an enormous protein containing with a molecular weight of 459.49 kDa (PDB ID: 6XR8). S-protein is a trimeric structure containing three indistinguishable chains where each chain is containing seven subunits. For such an enormous protein, it is fundamental to distinguish the right site for docking the ligands [18]. The protein was carefully analyzed and the correct subunit i.e., RBD of a single S-protein chain was chosen and the respective protein structure of RBD in the conformation interacting with ACE2 was retrieved from PDB (PDB ID 6M0J). The unique feature of this protein is that the conformation of RBD is open, where the amino acids interacting with ACE2 can be traced. Once the amino acids of the RBD chain of 6M0J were identified, their coordinates were chosen for performing the molecular docking of against 110 phytochemicals.

2.2. Ligands and protein preparation

A library of 110 compounds showing antiviral property from the plants W. somnifera [19], A. racemosus [20], Z. officinalis [21], A. sativum [22], C. longa [23], A. vasica [20] were constructed. All the ligands were prepared for docking by adding charges and hydrogen. These structures were energy minimized and aligned using the Amber03 force field algorithm [24].

Protein from PDB with ID 6M0J was chosen for the current study. This protein possessed two chains A and E. The resolution of the entire structure was 2.45 Å. Chain A corresponded to human ACE2 and consisted of 603 amino acids, while chain E was of RBD of monomeric spike protein and consisted of 229 amino acids. For further use, chain A was removed, and all the molecular docking was performed with chain E and the coordinates for the molecular docking corresponding to the interacting residues with chain ACE2 were chosen.

2.3. Molecular docking

The interactions of all the 110 ligands with the chain E (RBD of S-protein) for the protein 6M0J was performed using YASARA (Yet Another Scientific Artificial Reality Application) commercial package [25] software which employs the use of AutoDock Vina molecular docking algorithm [26]. Before performing docking, water molecules were removed from the.pdb file and then the energy minimizations was performed with the help of the YASARA NOVA steepest descent conjugate method in the YASARA structure. For docking, the following parameters were set: (i) number of binding modes- 10; (ii) exhaustiveness of search- 8 and (iii) maximum
energy difference: 3 kcal/mol. All the Interaction profile after performing docking so generated were also studied. Best pose based on binding energies for each ligand-protein interaction were further analyzed in ACCELRYS Discovery Studio (DS) visualizer for assessment hydrogen bond formation and for hydrophobic interactions by the functional groups of ligands with amino acids. From the interaction profile the ligands (hits) having high binding energy were further considered for the molecular dynamics approach. The binding free energy $\Delta G_{\text{bind}}$ was estimated according to Equation (1):

$$\Delta G = \Delta G_{\text{vdW}} \cdot + \Delta G_{\text{Hbond}} \cdot + \Delta G_{\text{elec}} \cdot + \Delta G_{\text{tor}} \cdot + \Delta G_{\text{desolv}}$$

(1)

where $\Delta G_{\text{vdW}}$ = van der Waals term for docking energy.

$\Delta G_{\text{Hbond}} = H$ bonding term for docking energy.

$\Delta G_{\text{elec}} = $ electrostatic term for docking energy.

$\Delta G_{\text{tor}} = $ torsional free energy term for ligand when the ligand transits from unbounded to bounded state.

$\Delta G_{\text{desolv}} = $ desolvation term for docking energy.

2.4. ADMET analysis

ADMET properties of the top 5 docked compounds was performed using pkCSM [27] and TOPKAT module of ACCELRYS Discovery Studio v 20.1. It computed in-vivo Absorption parameters like; Water solubility in buffer system (SK atomic types, mg/L), in-vivo Caco2 cell permeability (Human colorectal carcinoma), Human intestinal absorption (HIA, %), in-vivo P-glycoprotein inhibition and in-vivo skin permeability (logKp, cm/hour). Metabolic parameters were determined using in-vivo Cytochrome P450 2C19 inhibition, in-vivo Cytochrome P450 2C9 inhibition, in-vivo Cytochrome P450 2D6 inhibition, in-vivo Cytochrome P450 2D6 substrate, in-vivo Cytochrome P450 3A4 inhibition and in-vivo Cytochrome P450 3A4 substrate. Distribution property included tests like Blood-Brain Barrier (BBB) penetration, Lipinski’s Rule (Rule of Five), Central Nervous System (CNS) permeability. To access the toxicity of compounds under study a range of important endpoints including, Acute alage toxicity, Ames test, 2 years carcinogenicity bioassay in mouse, 2 years carcinogenicity bioassay in rat, in-vivo Ames test results in TA100 strain (Metabolic activation by rat liver homogenate) were computed. Excretion again is a very important parameter and as many drugs are often withdrawn at clinical trial stages due to their poorer renal clearance. In this study, we included Total Renal clearance and Renal OCT2 Substrate to identify the Excretion efficacy of the proposed metabolite.

2.5. Molecular dynamics (MD) simulations study

The physical movements of atoms and molecules of protein-ligand docked complex was identified through molecular dynamics simulation. Top scoring 5 compounds were chosen for the MD simulation at 100 ns time interval each. Molecular dynamics simulations study was carried out in Desmond (Schrodinger Release 2019–3). These complexes were prepared using a protein preparation wizard to allow complex relaxation. The addition of hydrogens, water removal, bond orders assignment, fill in missing side chains and loops with optimization of hydrogen-bond assignment (sampling of water orientations and use of pH 7.0) was done. The ligands were prepared using LigPrep of Maestro which adds hydrogen atoms, generates tautomers, ionization states, ring conformations, and produces minimized 3D structures. Whereas the protein was prepared by performing restrained minimization using OPLS-2005 force field. The system for simulation was built keeping solvent model as TIP3P, the boundaries were defined with the box shape of orthorhombic with the dimension of 10 Å × 10 Å × 10 Å. This was then followed by neutralization by Cl− or Na+ counter ions. Steepest descent energy minimization was performed, and the simulation was proceeded for 100 ns with NPT (constant Number of particles, Pressure, and Temperature) with 300 K and 1.01 bar, constant volume, Smooth Particle Mesh Ewald (PME) method. On completion of simulation the trajectories were analyzed in simulation interaction diagram wizard which analyzes trajectories for root mean square deviation (RMSD), root mean square fluctuation (RMSF), Ligand-protein contact profiles, for Ligand and Protein modifications [24,25,28].

2.6. Binding free energy calculations MM/GBSA

The single trajectory approach was used for the binding free energy calculation using molecular mechanics generalized Born surface area (MM/GBSA) [29–32]. From entire Simulation, a recording interval was adjusted to 100 ps for entire 100 ns of which 1000 number frames were gathered which were used to calculate MM/GBSA in PRIME module of Maestro 11.4. MM/GBSA calculations of entire trajectory was performed with the OPLS_2005 force field that use the VSCB 2.0 salvation model.

The free energy values were calculated using the following equations (2) and (3):

$$\Delta G_{\text{bind}} = \Delta G_{\text{complex(minimized)}} - \left[ \Delta G_{\text{ligand(minimized)}} + \Delta G_{\text{receptor(minimized)}} \right]$$

(2)

and

$$\Delta G_{\text{bind}} = \Delta G_{\text{MM}} + \Delta G_{\text{PB}} + \Delta G_{\text{SA-TDS}}$$

(3)

Where $\Delta G_{\text{TDS}}$ is the conformation entropic contribution, and $\Delta G_{\text{MM}}$ is the molecular mechanics’ interaction energy (electrostatic + van der Waals interaction) between protein and ligand. $\Delta G_{\text{PB}}$ and $\Delta G_{\text{SA}}$ depict the polar solvation energy and the nonpolar solvation energy, respectively.

3. Results

3.1. Spike protein assessment for identifying correct docking site

S-protein as a whole consists of three identical chains. Each of this chain possess two subunits, S1 and S2. Within the S1 subunit there exist two regions, N-terminal domain that is followed by the region of RBD. Based on the structure of SARS-CoV-2, the S1 and S2 subunits of S-protein monomers form the bulbous head and stalk region (Fig. 1a). In the pre-infection inactive state of SARS-CoV-2, S-protein exists as an inactive precursor. During its infection, target cell proteases activate the S-protein by cleaving it into S1 and S2 subunits, which is necessary for activating the membrane fusion domain after viral entry into target cells (Fig. 1b). Therefore, it is necessary to use the cleaved part of S1 to perform the docking to use the correct open conformation of RBD which ideally binds to ACE2 (Fig. 1c).

The rationale here is to mask the RBD in open conformation with phytochemical (lead compound) to inhibit its binding with ACE2. Therefore, protein PDB with ID 6M0J was chosen as this PDB entry possesses the open RBD region interacting with ACE2. For selecting 6M0J, all the assemblies of RBD interacting with ACE2 were retrieved from PDB in the priority of resolution “Best to Worse” and the PDB IDs of the assemblies were 6M0J, 6LZG, 6WV1, 3SCI, 3DOI, 2AJF, 7C8D, 3SCK, 3SCI, 3CJ and 3DOH. The RBD chains of all these
structures were superimposed to find the variation in the structural conformation. The RMSD was found to be 0.974 with respect to the best structure 6MJ0, and this protein structure showing the best resolution, it was chosen for the further experimental analysis. The ACE2 chain (Chain A, in this case, is removed) and the open conformation of RBD (Chain E) is used to perform molecular docking. The coordinates of residues (LYS417, GLU484, THR500, GLY446, TYR449, ASN487, GLY496, TYR449, ASN487, GLN493, ...
GLY502, TYR453, PHE486, LEU455, PHE486, TYR505, PHE486, TYR505) of RBD found to be interacting with ACE2 were chosen to perform the docking of test molecules from antiviral compounds from the plants W. somnifera, A. racemosus, Z. officinalis, A. sativum, C. longa, and A. vasa the list of molecules that were screened is provided in supplementary material file.

3.2. Molecular docking study

All the known anti-viral phytochemicals from our constructed library were docked at the specific site of the RBD. The coordinates that were chosen for performing docking involved all the amino acids that interact with ACE2 under natural conditions. The chosen site for docking involved the following amino acids: LYS417, GLU484, THR500, GLY446, TYR449, ASN487, GLY496, TYR449, ASN487, GLN493, GLY502, TYR453, PHE486, LEU455, PHE486, TYR505, PHE486, TYR505 and the set of these 18 amino acids are designated as Target Binding Locus (TBL). From all the docking analyses performed the top five compounds were screened based on two major criteria (i) Binding energy of ligand with target site on RBD and (ii) ability of the ligand to recruit the maximum number of amino acids from TBL. The top five phytochemicals possessing the ability to interact with RBD were found to be Racemoside A, Ashwagandhanolide, Withanoside VI, Withanoside IV and Racemoside C (Fig. 2).

From the docking analysis, Racemoside A showed the maximum TBL binding energy of 8.622 kcal/mol (Table 1) and could recruit and interact with ARG403, GLU406, GLN409, LYS417, TYR449, TYR453, LEU455, ILE472, GLY482, VAL483, GLY484, PHE490, LEU492, GLN493, SER494, TYR 495, GLY496, PHE497, GLN498, ASN501 and TYR505 from the dataset of docking obtained from YASARA. When the same best pose, pose with minimum Root Mean Square Deviation (RMSD) was viewed in DS, five hydrogen bonds, two carbon-hydrogen bonds, one pi-alkyl and one pi-pi T shaped bond formation were observed to be formed. Similarly, the second-best compound based on the binding energy was found to be Ashwagandhanolide, where the binding energy was found to be 8.346 kcal/mol and could interact with ARG403, TYR453, LEU455, PHE456, GLU484, TYR489, PHE490, GLN493, SER494, TYR495, GLY496, GLN498, THR500, ASN501 and TYR505 as per the docking dataset of YASARA (Table 1). DS showed Ashwagandhanolide to form five hydrogen bonds, three pi-pi T-shaped bonds and one unfavorable donor-donor bond formation. The third best compound based on the binding energy was Withanoside VI with the value of 8.083 kcal/mol and showed to interact with ARG403, TYR449, TYR453, LEU455, PHE456, GLU484, TYR485, PHE486, CYS488, TYR489, PHE490, GLN493, SER494, TYR495, GLY496, GLN498, ASN501 and TYR505. When analyzed in DS, only four hydrogen bonds were being formed along with two carbon-hydrogen bonds, two pi-alkyl interactions and formed one unfavorable donor-donor bonding. Racemoside C is the fifth and the last of the screened compound, it showed 7.915 kcal/mol of binding energy and showed to interact with ARG403, TYR449, TYR453, LEU455, PHE456, TYR489, GLN493, SER494, TYR495, GLY496, GLN498, THR500, ASN501, GLY502 and TYR505. It was found to make four hydrogen bonds, three carbon-hydrogen bonds and two pi-alkyl interactions. Based on the binding energy and capabilities to form hydrogen bonds, the top three compounds Racemoside A, Ashwagandhanolide, and Withanoside VI were further analyzed for their protein interactions by performing MD simulations. However, pharmacophore modelling and ADMET analysis of all the five screened compounds were performed. The structural properties of all the top five ligands are represented in Table 2 while the pharmacophore analysis of these phytochemical ligands is depicted in Fig. 3. All the top five screened compounds (Racemoside A, Ashwagandhanolide, Withanoside VI, Withanoside IV and Racemoside C) have several excellent structural features to interact with amino acids as these compounds have maximum proton donors and acceptors which is crucial to interact with amino acids by making hydrogen bonds. LogP values of Withanoside VI and Withanoside IV are identical and much lower than other screened compounds. On the contrary Ashwagandhanolide has the maximum LogP value suggesting its hydrophobic nature (Table 2).

3.3. ADMET analysis

All the ADMET properties of the top five screened compounds is depicted in Table 3. The key feature for any compound to serve as an oral drug is its movement across the intestinal epithelial barrier that determines its rate of movement and degree of human absorption which directly affects its bioavailability. For the computational model, high Caco-2 permeability would translate in predicted values greater than 0.90. Of all the compounds Ashwagandhanolide have Caco-2 value in positive range suggesting its moderate permeability, while all the other compounds (Racemoside A, Withanoside VI, Withanoside IV and Racemoside C) has a predicted value in negative range suggesting poor permeability. However, such compounds can be transported along with fat and through binding with albumin. Intestinal absorption (human) value predicts the absorption of the drug from an orally administered solution. Racemoside A, Ashwagandhanolide and Racemoside C have this value above 60% suggesting good absorption. While Withanoside VI and Withanoside IV have this value 39% and 31% respectively, suggesting their moderate to low absorption. All the compounds have highly similar skin permeability predicted values which are smaller than ~2.5 log Kp suggesting poor permeability. P-glycoprotein is a component of ATP-binding cassette (ABC) transporter, the value ‘yes’ for P-glycoprotein substrate suggests the compound can get transported across the cell membrane by ABC transporter. Here, all the five compounds are predicted to transport across ABC transporter. The volume of Distribution (VDss) suggests the total volume of drugs needed to be uniformly distributed in blood. The value below −0.15 logVDss stands for a low VDss value and above 0.45 LogVDss, which stands for considerably high VDss value. In this context, all the compounds in the current study has low VDss values. Blood-Brain barrier (BBB) permeability gives an account of the compound’s ability to reach the brain or not. It is presumed that compounds with logBB values greater than 0.3 can pass BBB therefore, all the compounds are not predicted to cross BBB, moreover, BBB permeability is not needed for targeting S-protein and so is not a desirable trait for the current objective. Moreover, all the compounds is expected to have Central Nervous System (CNS) permeability as for them, their logPS values is smaller than −2.0 which is good as only the drugs for the nervous system disease. Metabolism prediction suggested that all these screened compounds do not affect cytochrome functioning in a major way, where none of the compounds out of five is predicted to show CYP1A2, CYP2C19, CYP2C9, CYP2D6 and CYP3A4 inhibition. Renal excretion of all the compounds differ. None of the compounds show Ames toxicity suggesting these compounds does not possess
Fig. 2. (a) The interaction of RBD (Chain E of protein with PDB ID: 6M0J) with ACE2 (b) Shows the interaction of specific important amino acids of RBD with the best five docked compounds. Interaction of (c) Racemoside A (d) Ashwagandanolide (e) Withanoside VI (f) Withanoside IV and (g) Racemoside C with RBD in 2D view.
mutagenicity. All the compounds are not expected to show any Hepatotoxicity and Skin Sensitisation. The hERG I and II are potassium channels encoded by hERG, and their inhibition can cause QT syndrome (QT refers to the peaks of heart electrocardiogram) which affects the repolarization of the heart after a heartbeat. Their inhibition properties by screened phytochemicals are depicted in Table 3 along with other essential ADMET properties.

### 3.4. MD simulations

Racemoside A, Ashwagandhanolide and Withanoside VI were selected after secondary screening by assessing the properties of their interaction with RBD based on molecular docking, structural analysis based on pharmacophore profile and ADMET prediction. The complexes (i) RBD-Racemoside A, (ii) RBD-Ashwagandhanolide and (iii) RBD- Withanoside VI were then subjected to 100 ns of MD simulations.

After performing MD simulations, the Root Mean Square Deviation (RMSD) appraisal was performed which is utilized to quantify the normal change in dislodging of an of particles for a specific frame as for a reference constant frame. It is determined for all frames of trajectory. The plots in Fig. 3 depict RMSD movements in the portions of the protein (left Y-axis). The docked pose of ligand and protein in the complex is considered as the reference frame and the movement for this original alignment during MD simulation is gauged by aligning all the protein frames concerning time. Checking the RMSD of the protein can give knowledge into its auxiliary 3D structural movement on a graph during the simulation. RMSD examination can demonstrate if the simulation has equilibrated — its changes towards the finish of the recreation are around some thermal energetically stable conformation. Changes in the range of 1–4 Å are completely satisfactory for little, globular proteins. However, this range of value widens as the size of the protein increases. For the complex of RBD-Racemoside A (Fig. 3a) the protein backbone hovers the value of RMSD not exceeding 3.0 Å; for the RBD-Ashwagandhanolide complex (Fig. 3b), the value stays well under 4.0 Å and for the RBD- Withanoside VI complex (Fig. 3c), the value stays well under 3.5 Å for most of the simulation. Ligand RMSD (right Y-axis, plots of Fig. 3) suggests the stability of ligand posture concerning the docked position of the ligand in the binding cleft of the protein. 'Lig fit Prot' suggests the RMSD of a ligand for protein backbone. For this, the values slightly larger than the protein's RMSD are considered satisfactory but if the values observed are significantly larger than the RMSD of the protein, then

### Table 1

Binding energies and amino acid interaction profile of the top five hits obtained on performing molecular docking.

| Name           | Binding energy [kcal/mol] | The rank of the compound based on binding energy | Amino acid interaction profile |
|----------------|---------------------------|-------------------------------------------------|-------------------------------|
| Racemoside A   | 8.622                     | 1                                               | ARG403, GLU406, GLN409, LYS417, TYR449, TYR453, LEU455, ILE472, GLY482, VAL483, GLU484, PHE490, LEU492, GLN493, SER494, TYR495, GLY496, PHE497, GLN498, ASN501, TYR505 |
| Ashwagandhanolide | 8.346                   | 2                                               | ARG403, TYR453, LEU455, PHE456, GLU484, TYR489, PHE490, GLN493, SER494, TYR495, GLY496, GLN498, ASN501, TYR505 |
| Withanoside VI | 8.083                     | 3                                               | ARG403, TYR449, TYR453, GLU494, PHE485, PHE486, GLY487, PHE488, GLN498, TYR489, TYR505, PHE490, GLN493, SER494, TYR495, GLY496, GLN498, ASN501, TYR505 |
| Withanoside IV | 7.915                     | 4                                               | ARG403, TYR449, TYR453, PHE456, GLN493, SER494, TYR495, GLY496, GLN498, ASN487, CY500, ASN501, TYR505 |
| Racemoside C   | 7.906                     | 5                                               | ARG403, TYR449, TYR453, PHE456, TYR489, GLN493, SER494, TYR495, GLY496, GLN498, ASN501, TYR505 |

### Table 2

Structures and chemical properties of screened anti-viral phytochemicals.

| Descriptor          | Phytochemicals          |
|---------------------|-------------------------|
|                     | Racemoside A/C          | Ashwagandhanolide        | Withanoside VI            | Withanoside IV            | Racemoside C            |
| Molecular Weight    | 871.071                 | 975.295                 | 782.921                   | 782.921                   | 871.071                 |
| LogP               | 1.3216                  | 6.376                   | −0.0516                   | −0.1941                   | 1.3216                  |
| #Rotatable Bonds    | 7                       | 8                       | 8                         | 9                         | 7                       |
| #Acceptors         | 16                      | 13                      | 15                        | 15                        | 16                      |
| #Donors            | 8                       | 6                       | 9                         | 9                         | 8                       |
| Surface Area        | 359.006                 | 411.756                 | 321.42                    | 321.42                    | 359.006                 |

C.N. Patel, D. Goswami, D.G. Jaiswal et al. Journal of Molecular Graphics and Modelling 105 (2021) 107874
Fig. 3. MD simulation Protein-ligand interaction root-mean-square deviation (RMSD) profile of (a) RBD-Racemoside A (b) RBD-Ashwagandhanolide and (c) RBD-Withanoside VI complexes.
it is likely that the ligand acquires a different stable position than the original posture. For RBD-Racemoside A (Fig. 3a), the ligand likely acquires a different stable position than its original posture. For RBD-Racemoside A (Fig. 3a), the ligand acquires a different stable position than the original posture. For RBD-Racemoside A (Fig. 3a), it is likely that the ligand acquires a different stable position than the original posture. For RBD-Racemoside A (Fig. 3a), it is likely that the ligand is in a different stable position than the original posture. For RBD-Racemoside A (Fig. 3a), it is likely that the ligand acquires a different stable position than the original posture.

The Root Mean Square Fluctuation (RMSF) is useful for portraying confined changes along the protein chain (Fig. 4). In the graph, the peaks demonstrate regions of the protein that vary the most throughout the simulation. The graph shows that the protein chain exhibits highly fluctuating regions. The fluctuation is expected due to the dynamic nature of protein chains.

### Table 3

| Property          | Model Name | Phytochemicals |
|-------------------|------------|----------------|
|                   |            | Racemoside A/C |
|                   |            | Ashwagandhanolide |
|                   |            | Withanoside VI |
|                   |            | Withanoside IV |
| Absorption Intestinal absorption (human) | 63.519 | 63.819 | 39.364 | 31.451 |
| Absorption Skin Permeability | 2.735 | 2.735 | 2.735 | 2.735 |
| Absorption P-glycoprotein substrate | Yes | Yes | Yes | Yes |
| Absorption P-glycoprotein I inhibitor | Yes | Yes | Yes | Yes |
| Absorption P-glycoprotein II inhibitor | No | Yes | No | No |
| Distribution VDss (human) | -0.348 | -1.652 | -0.563 | -0.605 |
| Distribution Fraction unbound (human) | 0.349 | 0.249 | 0.408 | 0.398 |
| Distribution BBB permeability | -1.733 | -1.006 | -1.595 | -1.51 |
| Distribution CNS permeability | -4.281 | -2.859 | -4.412 | -4.436 |
| Metabolism CYP2D6 substrate | No | No | No | No |
| Metabolism CYP3A4 substrate | Yes | No | No | No |
| Metabolism CYP1A2 inhibitor | No | No | No | No |
| Metabolism CYP2C19 inhibitor | No | No | No | No |
| Metabolism CYP2C9 inhibitor | No | No | No | No |
| Metabolism CYP3A4 inhibitor | No | No | No | No |
| Excretion Total Clearance | 0.302 | 0.679 | 0.544 | 0.636 |
| Excretion Renal OCT2 substrate | No | No | No | No |
| Toxicity AMES toxicity | No | No | No | No |
| Toxicity Max. tolerated dose (human) | -2.635 | -0.058 | -1.925 | -1.94 |
| Toxicity hERG I inhibitor | No | No | No | No |
| Toxicity hERG II inhibitor | Yes | No | Yes | Yes |
| Toxicity Oral Rat Acute Toxicity (LD50) | 3.025 | 3.704 | 2.875 | 2.886 |
| Toxicity Oral Rat Chronic Toxicity (LOAEL) | 2.511 | 1.49 | 3.501 | 3.501 |
| Toxicity Hepatotoxicity | Yes | No | No | No |
| Toxicity Skin Sensitisation | No | No | No | No |
| Toxicity T. pyriformis toxicity | 0.285 | 0.285 | 0.285 | 0.285 |
| Toxicity Minnow toxicity | 9.971 | 2.486 | 7.489 | 6.847 |

| Property          | Model Name | Phytochemicals |
|-------------------|------------|----------------|
|                   |            | Racemoside A/C |
|                   |            | Ashwagandhanolide |
|                   |            | Withanoside VI |
|                   |            | Withanoside IV |
| Metabolism CYP2D6 substrate | No | No | No | No |
| Metabolism CYP3A4 substrate | Yes | No | No | No |
| Metabolism CYP1A2 inhibitor | No | No | No | No |
| Metabolism CYP2C19 inhibitor | No | No | No | No |
| Metabolism CYP2C9 inhibitor | No | No | No | No |
| Metabolism CYP3A4 inhibitor | No | No | No | No |
| Excretion Total Clearance | 0.302 | 0.679 | 0.544 | 0.636 |
| Excretion Renal OCT2 substrate | No | No | No | No |
| Toxicity AMES toxicity | No | No | No | No |
| Toxicity Max. tolerated dose (human) | -2.635 | -0.058 | -1.925 | -1.94 |
| Toxicity hERG I inhibitor | No | No | No | No |
| Toxicity hERG II inhibitor | Yes | No | Yes | Yes |
| Toxicity Oral Rat Acute Toxicity (LD50) | 3.025 | 3.704 | 2.875 | 2.886 |
| Toxicity Oral Rat Chronic Toxicity (LOAEL) | 2.511 | 1.49 | 3.501 | 3.501 |
| Toxicity Hepatotoxicity | Yes | No | No | No |
| Toxicity Skin Sensitisation | No | No | No | No |
| Toxicity T. pyriformis toxicity | 0.285 | 0.285 | 0.285 | 0.285 |
| Toxicity Minnow toxicity | 9.971 | 2.486 | 7.489 | 6.847 |
Fig. 4. MD simulation Protein-ligand interaction root-mean-square fluctuation (RMSF) profile of (a) RBD-Racemoside A (b) RBD-Ashwagandhanolide and (c) RBD-Withanoside VI.
which deposits communicate with the ligand in every direction
outline. A few residues make more than one explicit contact with
the ligand, which is shown by a hazier shade of orange, as
indicated by the scale to one side of the plot. These plots are very
crucial suggesting these three compounds viz. Racemoside A,
Ashwagandhanolide, and Withanoside VI interact with the amino
acids throughout the simulation and are not dissociating away from
their interacting site, however, the variations in the RMSD and
RMSF values of the ligand as showed in Figs. 3 and 4 respectively,
suggest that these ligands may be reorienting themselves during
the simulation.

3.5. MM/GBSA binding free energy calculations

Post simulation analysis of all the three the complexes RBD-
Racemoside A, RBD-Ashwagandhanolide and RBD-Withanoside VI
were performed by taking snapshots of the trajectory profiles
developed on performing 100 ns MD simulation and is depicted in
Table 4. Binding free energy change calculation provides an insight
into the ligand potential to strongly interact with the amino acids
of the protein. The energy released (ΔGbind) due to bond formation,
or rather interaction of the ligand with protein is in the form of
binding energy and it determines the stability of any given
protein–ligand complex. The free energy of a favourable reaction is
negative. It is observed that all the top three ligands have ΔGbind in
the negative range. All the three compounds, tend to have similar
energies corresponding to van der Waals interactions represented
as ΔGvdW, suggesting these compounds tends to stay in the vi-
cinity of the interacting amino acids of RBD. All the three com-
pounds show negative values for Coulomb energy which describe
the potential energy in systems. The negative value suggests that
these ligands while interacting with RBD has poor potential energy,
suggesting better stability as the ligands do not have enough po-
tential energy to get destabilized. In addition to the total energy, the
contributions to the total energy from different components such
as Hydrogen-bonding correction, Lipophilic energy, Pi-pi packing
correction and van der Waals energy is provided in Table 4.

4. Discussion

The S-protein has been the hype owing to its high degree of
similarity existing amongst SARS-CoV and SARS-CoV-2, where
89.8% sequence identity is found amongst their S2 subunits, which
mediate the membrane fusion process [33,34]. While both of their
S1 subunits utilize ACE2 as the receptor to infect human cells but
the S1 subunit of SARS-CoV-2 shows 10-fold more ACE2 binding
affinity. Such striking similarity is not found for other proteins of
SARS-CoV and SARS-CoV-2, this has raised the speculation in the
minds of researchers, that SARS-CoV-2 may possess the reengi-
neered version of S-protein from SARS-CoV’s. After binding of RBD
in the S1 subunit of S-protein with ACE2 receptor of human cell, the
heptad repeat 1 (HR1) and 2 (HR2) domains in its S2 subunit of S-
protein interact with each other to form a six-helix bundle (6-HB)
fusion core, bringing viral and host cell membranes into proximity
for fusion and infection [33]. Blocking this phenomenon has huge
potentials to stop the infection of virus and finding RBD inhibitors is
of huge potentials, where researchers have even tried to block RBD
with Human recombinant soluble ACE2 and other similar peptides
[35–40]. A natural food preservative peptide nisin can interact with
the SARS-CoV-2 spike protein receptor human ACE2 is reported
[41]. Fusion inhibitor, and the S-protein inhibitors in current study
specifically inhibit this process of membrane fusion stopping the
entry of viral components entering into the host cell [15]. As an
effort to develop such inhibitors, EK1 peptide was created which
focused explicitly HR1 subunit and have indicated promising re-
actions for in vivo mice model as well [33]. With restricted exten-
sion to work with SARS-CoV-2, as it requires Biosafety Level 4
(BSL4) arrangement, increasingly more exploration is been
distributed with in silico approach with docking and MD simula-
tions being the foundation of the computational examination,
regardless of such examination ailing in vitro investigations,
gigantic volumes of information demonstrating the collaborations

Fig. 5. Ligand properties for best hits such as RMSD, the radius of gyration (rGyr),
intramolecular hydrogen bonds (intraHB), Molecular Surface Area (MolSA), Solvent
Accessible Surface Area (SASA), Polar Surface Area (PSA) on interacting with protein
during MD simulation.
Fig. 6. Protein-Ligand interaction profile of RBD-Racemoside A complex (a) interaction profile of crucial interacting amino acids (b) timeline representation of the interactions of amino acids.
Fig. 7. Protein-Ligand interaction profile of RBD-Ashwagandholide complex (a) interaction profile of crucial interacting amino acids (b) timeline representation of the interactions of amino acids.
Protein-Ligand interaction profile of RBD-Withanoside VI complex (a) interaction profile of crucial interacting amino acids (b) timeline representation of the interactions of amino acids.
of a functioning drug compound or phytochemical with the viral protein has been brought to the analysts area, which can come very handy for those having facility of performing in vitro examinations for approving computational estimates at last sparing a ton of time.

Under current study we have first constructed a library of 110 compounds from the medicinal plants *W. somnifera* [19], *A. racemosus* [20], *Z. officinalis* [21], *A. sativum* [22], *C. longa* [23], *A. vasica* [20]. There are reports where the RBS of S-protein is focused to veil this site communicating with ACE2, where phytochemicals from Glycyrrhiza glabra are imagined to collaborate and obstruct the ACE2 restricting amino corrosive buildups of S-protein [17]. Efforts are also made for repurposing approved drugs as inhibitors of S-protein of SARS-CoV-2 where the authors have proposed 10 FDA approved drugs showing potentials to interact and mask the RBD [42]. Of lately, strategy of repurposing the approved small molecule drugs in order to inhibit SARS-CoV-2 S-protein and human ACE2 interaction through virtual screening approaches is used where drugs, Diammonium Glycyrrhizinate, Digitoxin, Ivermectin, Rapamycin, Rifaximin, and Amphotericin B represented the most desirable features to serve as RBD blockers [43]. Similar other study showed laxative drug, Bisoxatin to have potentials act as RBD blocker [44]. S-protein is additionally focused with the most ordi

| Ligand               | ΔGBind (Kcal/mol) | ΔGCoulomb (Kcal/mol) | ΔGBond (Kcal/mol) | ΔGLipo (Kcal/mol) | ΔGPacking (Kcal/mol) | ΔGvdW (Kcal/mol) |
|---------------------|-------------------|----------------------|-------------------|-------------------|---------------------|-------------------|
| Racemoside A        | –89.06            | –34.83               | –4.45             | –55.81            | –5.25               | –54.51            |
| Ashwagandanolide     | –93.22            | –37.52               | –3.32             | –70.52            | –4.29               | –57.34            |
| Withanoside VI      | –78.64            | –40.12               | –2.56             | –66.23            | –3.36               | –53.49            |

Note, meaning of abbreviations used in the table are as follows: Coulomb—Coulomb energy. Hbond—Hydrogen-bonding correction. Lipo—Lipophilic energy. Packing—Pi-Pi packing correction. vdW—Van der Waals energy.

As of late, our research group proposed Pyranonigrin A and Flavilolin to have the possibilities to interact with MPRO and hinder its viral replication capacity [9]. Another gathering of specialists has comparably recognized mixes from Tea plants that have the possibilities to associate with MPRO and restrain its capacity [48,49]. The subsequent methodology is to check the accessible commercial drugs to market against the SARS-CoV-2. There may be an exceptionally high possibility that current medications may interfere with the biochemical cycles of the virus and restrain it. Such a methodology is called drug repurposing. Utilizing drug repurposing, Procaainamide, Tetrahydrozoline, Levamisole was distinguished as medications that can meddle with the papain-like protease of SARS-CoV-2 [50]. Such a methodology utilizes molecular docking and molecular dynamics as the center strategies for the in-silico examination, and by utilizing these techniques several lead compounds are recognized to have potential to meddle with the biochemistry and life cycle of SARS-CoV-2 as of late. There are a few spaces of life sciences where the approaches of docking and MD reproductions have been of an incredible use [51–53]. Comparable examinations utilizing docking and MD reproductions are likewise performed for accessing the potency of hydroxchloroquine with various targets of SARS-CoV-2 [54].

Looking through compounds that can restrain SARS-CoV-2 is of the most elevated need for the scientific fraternity. To commercialize such compounds, molecules from natural plant and microbe are been looked for, because of their low harmfulness, simple extraction and being effectively acknowledged by individuals. Such medications likewise have more limited periods of preliminaries. *W. somnifera* is known as Ashwagandha and is an important medicinal plant containing plethora of pharmacologically important triterpenoid steroidal lactones, which are collectively termed as withanolides. The importance of phytochemicals from Ashwagandha for their antiviral properties are widely described [55]. Ashwagandanolide, a bioactive dimeric thiowithanolide isolated from the roots of Ashwagandha. Previously Ashwagandholide was evaluated for its ability to inhibit cell proliferation against human lung (NCI H–460), breast (MCF7), colon (HCT–116), CNS (SF–268), and gastric (AGS) tumor cell lines using the MTT cell viability assay, as described earlier [56]. More recently, several compounds of Ashwagandha has been reported to inhibit MPRO of SARS-CoV-2 [57]. Further, compounds from Ashwagandha that were able to inhibit MPRO were Withanoside II, Withanoside IV, Withanoside V and Sitoindoside IX. Under current study the other compounds that can block the RBD of S-protein are Racemoside A, Withanoside VI, Withanoside IV and Racemoside C. Withanosides are also found to be in significant amounts from Ashwagandha and they are known to improved Abeta-induced memory impairment, neurite atrophy, and synaptic loss in the cerebral cortex and hippocampus in mice. Withanoside VI is also known to facilitates the regeneration of axons and dendrites by reconstructing pre- and post-synapses in neurodegenerative diseases and preventing pathogenesis and neuronal death. Withanoside VI is important candidate for the therapeutic treatment of neurodegenerative diseases. There are at least eleven different types of Withanosides found in Ashwagandha [58]. Off late Withanoside X, is also reported to inhibit SARS-CoV-2 viral entry in to the cell [59]. Moreover, this corroborates with our results too where we have three phytochemicals namely Ashwagandholide, Withanoside VI and Withanoside IV of *W. somnifera* have shown exceptional potency to interact with RBD of S-protein and inhibit its interaction with ACE2 ultimately blocking the entry of viral particle in to the human host. The other two important phytochemicals to have shown similar potency belongs to the plant *A. racemosus* and these phytochemicals are Racemoside A and Racemoside C. Racemosides are natural steroidal saponins and are well-known to have anti-leishmanial properties [60]. Moreover, Racemosides are also reported to interact with S-protein and other structural proteins of SARS-CoV-2 [61].

To summarize the entire study, to start with we have used the standard workflow used for “receptor-based drug designing” which deals screening and selecting top hits of phytochemicals based on docking, then verifying the interactions with simulation. The
interaction screened phytochemicals with human body is predicted with ADMET and as an add on to see which structural features of screened phytochemicals can interact with amino acids, we have performed pharmacophore mapping. For the study we created the library of 110 compounds from the medicinal plants W. sommifera, A. racemosa, Z. officinalis, A. sativum, A. longa and A. vasica, of which we found Racemose A, Ashwangandhole and Withanoside VI to be the most potent molecules to bind RBD thereby blocking its interaction with RBD.

Compliance with ethical standards
This article does not contain any studies with human participants or animals performed by any of the authors.

Authors contributions
CP, DG and DJ conceptualized and designed the project. CP and DG acquired data and wrote the manuscript. CP and DG analyzed and interpreted data. HP, RP and HS provided technical support. HP supervised the study. The whole manuscript was approved by all authors.

Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments
The Financial Assistance Programme – Department of Science and Technology [Grant number GSBTM/MD/DDR/1409/2017–18] and Gujarat Council on Science and Technology [GUCOST/Supercomputer/2019–20/1359] had provided grants for the purchase of computer hardware only and is been used up. The research work is not been granted from any fund. The authors gratefully acknowledge the Department of Botany, Bioinformatics and Climate Change Impacts Management, Gujarat University for providing an opportunity to access the bioinformatics research facilities.

References
[1] D.A. Schwartz, A.L. Graham, Potential maternal and infant outcomes from coronavirus 2019-nCoV (SARS-CoV-2) infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections, Viruses 12 (2020), https://doi.org/10.3390/v12091914.
[2] K.S. Joshi, S.S. Jagdale, S.B. Bansode, S. Shiva Shankar, M.B. Tellis, K. Pandya, A. Chugh, A.P. Giri, M.J. Kulkarni, S. Joshi, Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease, J. Biomol. Struct. Dyn. (2020) 1–16, https://doi.org/10.1080/07391102.2020.1759317.
[3] Y. Chen, Y. Guo, Y. Pan, Z.J. Zhao, Structure analysis of the receptor binding of 2019-nCoV. Biochem. Biophys. Res. Commun. (2020), https://doi.org/10.1016/j.bbrc.2020.02.071.
[4] Z. Song, Y. Xu, L. Bao, L. Zhang, P. Yu, Y. Qu, H. Zhu, W. Zhao, Y. Han, C. Qin. From SARS to MERS, thrusting coronaviruses into the spotlight, Viruses 11 (2019), https://doi.org/10.3390/v110100599.
[5] F. Wu, S. Zhao, B. Yu, Y.M. Chen, W. Wang, Z.G. Song, Y. Hu, Z.W. Tao, J.H. Tian, Y.Y. Pei, M.L. Yuan, Y.Z.Y.Z. Zhang, F.H. Dai, Y. Liu, Q.M. Wang, J.J. Zheng, X. Xu, E.C. Holmes, Y.Z.Y.Z. Zhang, A novel coronavirus associated with human respiratory disease in China, Nature 579 (2020) 265–269, https://doi.org/10.1038/s41586-020-2838-2.
[6] P. Rao, A. Shukla, P. Parmar, R.M. Rawal, B. Patel, M. Saraf, D. Goswami. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation, Biophys. Chem. (2020) 106425, https://doi.org/10.1016/j.bcp.2020.106425.
[7] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, Y. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, C. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (2020) 497–506, https://doi.org/10.1016/S0140-6736(20)30183-5.
[8] R. Kooistra, C. Yang, R. Yu, M. Liu, F. Wang, J. Hu, X. Guo. COVID-19 Docking Server: an Interactive Server for Docking Small Molecules, Peptides and Antibodies against Potential Targets of COVID-19, J ArXiv Prepr. (2020). https://arxiv.org/abs/2003.00163.
[9] P.A.R. A. Shukla, P. Parmar, B. Patel, M. Saraf, D. Goswami. Proposing a fungal metabolite-Flavilolin as a potential inhibitor of 3Clpro of novel coronavirus SARS-CoV-2 identified using Docking and Molecular Dynamics, J. Biomol. Struct. Dyn. (2020), https://doi.org/10.1080/07391102.2020.1813202.
[10] X. Chen, R. Li, Z. Pan, C. Qian, Y. Yang, R. You, J. Zhao, P. Liu, L. Gao, Z. Li, Q. Huang, L. Xu, J. Tang, Q. Tian, W. Yao, L. Hu, X. Yan, X. Zhou, Y. Wu, K. Deng, Z. Zhang, Z. Qian, Y. Chen, L. Ye, Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor, Cell. Mol. Immunol. 17 (2020) 647–649, https://doi.org/10.1038/s41423-020-0426-7.
[11] J. Shang, Y. Wan, C. Luo, G. Ye, Q. Geng, A. Auerbach, F. Li, Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. U. S. A 117 (2020), https://doi.org/10.1073/pnas.2003138117.
[12] X. Ou, Y. Liu, L. Lei, P. Li, M. Li, L. Ren, L. Guo, R. Guo, T. Chen, J. Hu, Z. Xiang, Z. Mu, X. Chen, J. Chen, K. Hu, Q. Jin, J. Wang, Z. Qian, Characterization of spike glycoprotein of SARS-CoV-2 virus entry and its immune cross-reactivity with SARS-CoV, Nat. Commun. 11 (2020), https://doi.org/10.1038/s41467-020-15562-9.
[13] J. Zhang, G. Ye, K. Shi, Y. Wan, C. Luo, H. Alhara, Q. Geng, A. Auerbach, F. Li, Structural basis of receptor recognition by SARS-CoV-2, Nature 581 (2020) 221–224, https://doi.org/10.1038/s41586-020-2179-y.
[14] A. Trezza, D. Iovinelli, A. Santucci, F. Prischi, O. Spiga. An integrated drug repurposing approach for the rapid identification of potential SARS-CoV-2 viral inhibitors, Sci. Rep. 10 (2020) 1–8, https://doi.org/10.1038/s41598-020-70863-9.
[15] S. Xia, L. Yan, W. Xu, A.S. Agrawal, A. Algaiissi, C.T.K. Tseng, Q. Wang, L. Du, W. Tan, I.A. Wilson, S. Jiang, B. Yang, L. Lu, A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike, Sci. Adv. 5 (2019) eaav4580, https://doi.org/10.1126/sciadv.aav4580.
[16] S. Xia, Y. Zhu, M. Liu, Q. Lan, W. Xu, Y. Wu, T. Ying, S. Li, Z. Shi, J. Jiang, L. Lu, Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein, Cell, Mol. Immunol. 17 (2020) 765–767, https://doi.org/10.1038/s41423-020-0374-2.
[17] S.K. Sinha, S.K. Prasad, M.A. Islam, S.S. Gurav, R.B. Patil, N.A. AlFaris, T.S. Majeed, N.M. Alshehery, S.M. Wabaidur, A. Shalaby, Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and nonstructural protein-15: a pharma-}
O.V. de Oliveira, G.B. Rocha, A.S. Paluch, L.T. Costa, Repurposing approved drugs as inhibitors of SARS-CoV-2 targeting its entry into the host cells, Drugs R 20 (2020) 161–169, https://doi.org/10.1007/s12038-020-00132-5.

F.-C. Wong, J.-H. Ong, T.-T. Chai, Identification of PUTATIVE CELL-ENTRY-INHIBITORY Peptides against SARS-CoV-2 from Edible Insects: an in Silico Study, Efood, 2020, https://doi.org/10.2991/efood.k.200918.002.

M. Alagumuthu, S. Rajpoot, M. Alagumuthu, S. Rajpoot, U. Saqib, Identification of bioactive molecule from Withania somnifera (Ashwagandha) withanolide isolated from the roots of Withania somnifera, J. Nat. Prod. 69 (2006) 2020, pp. 139–145, https://doi.org/10.1021/an050101c.

D. Schütz, Y.B. Ruiz-Blanco, J. Münch, F. Kirchhoff, E. Sanchez-Garcia, I.A. Müller, Peptide and peptide-based inhibitors of SARS-CoV-2 entry, Adv. Drug Deliv. Rev. 167 (2020) 47–65, https://doi.org/10.1016/j.addr.2020.110727.

B. Rathod, P.R. Prapajati, L.B. Punjabi, K.N. Prapajati, N. Chauhan, M.F. Mansuri, Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2, Silico Pharmacol. 8 (2020), https://doi.org/10.1007/s40268-020-00355-x.

R. Bhattacharya, A.M. Gupta, S. Mitra, S. Mandal, S.R. Biswas, A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2, Virology 552 (2021) 107–111, https://doi.org/10.1016/j.virol.2020.11.007.

O.V. de Oliveira, G.B. Rocha, A.S. Paluch, L.T. Costa, Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening, J. Biomol. Struct. Dyn. (2020) 1–10, https://doi.org/10.1080/07391102.2020.1772885.

H. Kalhor, S. Sadeghi, H. Abolhasani, R. Kalhor, H. Rahimi, Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches, J. Biomol. Struct. Dyn. (2020), https://doi.org/10.1080/07391102.2020.1824815.

S. Unni, S. Aoufi, S. Tiyyagarajan, B. Padmanabhan, Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods, J. Biosci. 45 (2020), https://doi.org/10.1007/s12038-020-00122-w.

P. Pandey, J.S. Rane, A. Chatterjee, A. Kumar, R. Khan, A. Prakash, S. Ray, Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development, J. Biomol. Struct. Dyn. (2020) 1–11, https://doi.org/10.1080/07391102.2020.1768011.

Z.T. Muhsen, A.R. Hameed, H.M.H. Al-Hasani, M. Tahir uq Marag, G. Li, Promiscuous terpenes as SARS-CoV-2 spike receptor-binding domain (RBD) attachment inhibitors to the human ACE2 receptor: integrated computational approach, J. Mol. Liq. 320 (2020), 114493, https://doi.org/10.1016/j.jol.2020.114493.

K. Ravichandran, M. Sankar, In silico molecular docking analysis of targeting SARS-CoV-2 spike protein and selected herbal constituents, Artic. J. Pure Appl. Microbiol. (2020), https://doi.org/10.22207/JPAM.14.291.137.

V.K. Bhardwaj, R. Singh, J. Sharma, V. Rajendran, R. Purohit, S. Kumar, Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors, J. Biomol. Struct. Dyn. (2020) 1–10, https://doi.org/10.1080/07391102.2020.1766572.

V.K. Bhardwaj, R. Purohit, Targeting the protein–protein interface pocket of Aurora-A–TPX2 complex: rational drug design and validation, J. Biomol. Struct. Dyn. (2020), https://doi.org/10.1080/07391102.2020.1772109.

S. Xia, M. Liu, C. Wang, W. Xu, Q. Lan, S. Feng, F. Qi, L. Bao, L. Du, S. Liu, C. Qin, F. Sun, Z. Shi, Y. Zhu, S. Jiang, L. Lu, Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion, Cell Res. 30 (2020) 343–355, https://doi.org/10.1038/s41422-020-0305-x.

R. Yu, L. Chen, R. Lan, R. Shen, P. Li, Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking, Int. J. Antimicrob. Agents 56 (2020), 106012, https://doi.org/10.1016/j.ijantimicag.2020.106012.

J. Yang, S. Petitjean, S. Derclaye, M. Koehler, Q. Zhang, A. Dumitruc, P. Soumillion, D. Alsteens, Molecular interaction and inhibition of SARS-CoV-2 spike protein binding to the ACE2 receptor, Res. Sq. (2020), https://doi.org/10.21203/rs.3.rs-30468/v1.

M.S. Baig, M. Alagumuthu, S. Rajpoot, U. Saqib, Identification of a potential peptide inhibitor of SARS-CoV-2 targeting its entry into the host cells, Drugs R 20 (2020) 161–169, https://doi.org/10.1007/s12038-020-00132-5.

F.-C. Wong, J.-H. Ong, T.-T. Chai, Identification of Putative Cell-Entry-Inhibitory Peptides against SARS-CoV-2 from Edible Insects: an in Silico Study, Efood, 2020, https://doi.org/10.2991/efood.k.200918.002.

M. Alagumuthu, S. Rajpoot, M.S. Baig, Structure-based design of novel peptidomimetics targeting the SARS-CoV-2 spike protein, Cell. Mol. Bioeng. (2020), https://doi.org/10.1016/j.cmbb.2020.06.008-5.

D. Schütz, Y.B. Ruiz-Blanco, J. Münch, F. Kirchhoff, E. Sanchez-Garcia, I.A. Müller, Peptide and peptide-based inhibitors of SARS-CoV-2 entry, Adv. Drug Deliv. Rev. 167 (2020) 47–65, https://doi.org/10.1016/j.addr.2020.110727.

S.B. Rathod, P.R. Prapajati, L.B. Punjabi, K.N. Prapajati, N. Chauhan, M.F. Mansuri, Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2, Silico Pharmacol. 8 (2020), https://doi.org/10.1007/s40268-020-00309-5.

R. Bhattacharya, A.M. Gupta, S. Mitra, S. Mandal, S.R. Biswas, A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2, Virology 552 (2021) 107–111, https://doi.org/10.1016/j.virol.2020.11.007.

O.V. de Oliveira, G.B. Rocha, A.S. Paluch, L.T. Costa, Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening, J. Biomol. Struct. Dyn. (2020) 1–10, https://doi.org/10.1080/07391102.2020.1772885.

H. Kalhor, S. Sadeghi, H. Abolhasani, R. Kalhor, H. Rahimi, Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches, J. Biomol. Struct. Dyn. (2020), https://doi.org/10.1080/07391102.2020.1824815.

S. Unni, S. Aoufi, S. Tiyyagarajan, B. Padmanabhan, Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods, J. Biosci. 45 (2020), https://doi.org/10.1007/s12038-020-00122-w.